Bipartisan Bill Would Make Investments in Domestic Prescription Drug and Medical Device Manufacturing to Address Supply Chain Issues 

WASHINGTON, D.C. – Today, U.S. Senator Jacky Rosen (D-NV) announced she has joined Senator Tim Scott in introducing the MADE in America Act, bipartisan legislation which would address vulnerabilities in the U.S. pharmaceutical supply chain and bolster pharmaceutical independence through investments in domestic prescription drug and medical device manufacturing. Companion legislation has been introduced in the U.S. House of Representatives by Congressmen Darren Soto (D-FL), Earl Carter (R-GA), and Tom Rice (R-SC).

“The COVID-19 pandemic has shown just how critical it is to bolster our domestic supply chain and strengthen our health care system,” said Senator Rosen. “The MADE in America Act will work to further grow our domestic drug and medical device manufacturing, and address ongoing drug shortages by improving FDA coordination and identifying specific barriers. I will continue working to grow our U.S. medical supply chain, invest in good paying jobs, and protect Nevada communities and access to critical medical supplies.”

BACKGROUND: The MADE in America Act would incentivize the domestic manufacturing of drugs, API, PPE, and diagnostics in order to make the U.S. supply chain less dependent on foreign countries. This independence is achieved through a new tax credit that would only apply to manufacturers operating in certain Opportunity Zones across the United States. The tax credit will work to bring manufacturing back to the United States through incentives aimed at leveling the playing field.

Additionally, the MADE in America Act includes measures aimed at mitigating drug shortages including improving FDA reporting of facility inspections, improving coordination among offices at FDA, and creating a regulatory pathway for emerging technology in manufacturing.

###

Issues